According to Zhitong Finance App News, Kangyuan Pharmaceutical (600557.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved operating income of 1,661 billion yuan, up 1.21% year on year; net profit attributable to shareholders of listed companies was 147 million yuan, up 3.36% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 129 million yuan, up 7.46% year on year; basic earnings per share were 0.26 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.